Management of Chronic Hepatitis C Virus Infection: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases-2023 Update

Erişim
info:eu-repo/semantics/openAccessTarih
2023Yazar
Aygen, BilgehanGurbuz, Yunus
Cetinkaya, Riza Aytac
Cinar, Gule
Kayabas, Uner
Ormen, Bahar
Korkmaz, Pinar
Üst veri
Tüm öğe kaydını gösterÖzet
Direct-acting antiviral (DAA) drugs have increased the effectiveness of treatment in hepatitis C patients. With the developments in the world and DAA drugs coming into use in our country, the consensus report on the management of hepatitis C virus (HCV) infection has needed to be updated. It was first published in 2014 and updated in 2017 by the Viral Hepatitis Study Group of the Turkish Society of Clinical Microbiology and Infectious Diseases. Here, the Study Group has reviewed every aspect of chronic hepatitis C and revised the consensus report with the updated information. At the end of each the recommendations are summarized, the reimbursed in our
Cilt
36Bağlantı
https://doi.org/10.36519/kd.2023.4672https://search.trdizin.gov.tr/tr/yayin/detay/1257111
https://hdl.handle.net/20.500.12933/2755















